TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurocrine ( (NBIX) ) has issued an update.
On June 2, 2025, Sanjay Keswani, M.D. took over as Chief Medical Officer of Neurocrine Biosciences, Inc., succeeding Eiry W. Roberts, M.D. In conjunction with this leadership change, Dr. Roberts transitioned to a role as Strategic Advisor, with her employment term extended until December 31, 2026, following an amendment to her employment agreement made on November 21, 2025.
The most recent analyst rating on (NBIX) stock is a Buy with a $157.00 price target. To see the full list of analyst forecasts on Neurocrine stock, see the NBIX Stock Forecast page.
Spark’s Take on NBIX Stock
According to Spark, TipRanks’ AI Analyst, NBIX is a Outperform.
Neurocrine’s strong financial performance and positive earnings call are the primary drivers of its stock score. While technical indicators suggest some short-term weakness, the company’s strategic initiatives and robust revenue growth outlook support a favorable long-term view. Valuation remains a consideration, with a higher P/E ratio reflecting growth expectations.
To see Spark’s full report on NBIX stock, click here.
More about Neurocrine
Neurocrine Biosciences, Inc. operates in the biopharmaceutical industry, focusing on developing treatments for neurological and endocrine-related disorders.
Average Trading Volume: 938,669
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14.14B
See more data about NBIX stock on TipRanks’ Stock Analysis page.